MSMerve Sıkık

Merve Sıkık

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Merve Sıkık has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Design, Synthesis, Biological Evaluation, and Molecular Modeling Studies of Novel 2‐Aminothiazole Derivatives as Potential FOXM1 Inhibitors for Triple‐Negative Breast Cancer Therapy and Structure‐Activity Relationship

    by Khaled A N Abusharkh, Venhar Çınar, Alper Onder, Merve Sıkık, Zuhal Hamurcu, Bulent Ozpolat, Mehmet Ay, Ferah Comert Onder

    Triple Negative Breast Cancer (TNBC) is one of the most aggressive subtypes of breast cancer (BC), which is associated with a very poor prognosis. It is a broad category of tumors with a variety of biological, clinical, and morphological characteristics. FOXM1 is a pivotal transcription factor that modulates proliferation‐associated genes through complex protein‐DNA and protein‐protein interactions, making it a highly attractive target in cancer therapy. However, existing small‐molecule inhibitors often suffer from limited specificity and efficacy. In this study, we designed, synthesized, and evaluated novel series of 2‐aminothiazole derivatives ( C1‐C15) as potential FOXM1 inhibitors. Molecular docking and molecular dynamics (MD) simulations were employed to investigate the binding interactions of these compounds with the FOXM1 DNA‐binding domain (FOXM1‐DBD). Structural analysis highlighted the importance of crucial residues, including Asn283, His287, and Arg286, in mediating inhibitory activity. Among the synthesized compounds, C11 exhibited remarkable structural alignment and interaction patterns with FOXM1‐DBD, comparable to the reference inhibitor FDI‐6. In vitro studies using TNBC cell lines (MDA‐MB‐231, BT‐549, and BT‐20) demonstrated that compound C11 significantly outperformed FDI‐6 in potency. Western blot analysis revealed that C11 effectively suppressed FOXM1 transcriptional activity at concentrations of 10 µM in BT‐549 cells and 20 µM in MDA‐MB‐231 cells. These findings underscore the potential of C11 as a potent FOXM1 inhibitor and highlight its promise for further development in TNBC therapy.


  • Open Access

    Novel benzothiazole/benzothiazole thiazolidine‐2,4‐dione derivatives as potential FOXM1 inhibitors: In silico, synthesis, and in vitro studies

    by Khaled A. N. Abusharkh, Ferah Comert Onder, Venhar Çınar, Alper Onder, Merve Sıkık, Zuhal Hamurcu, Bulent Ozpolat, Mehmet Ay

    The oncogenic transcription factor FOXM1 overexpressed in breast and other solid cancers, is a key driver of tumor growth and progression through complex interactions, making it an attractive molecular target for the development of targeted therapies. Despite the availability of small‐molecule inhibitors, their limited specificity, potency, and efficacy hinder clinical translation. To identify effective FOXM1 inhibitors, we synthesized novel benzothiazole derivatives (KC10–KC13) and benzothiazole hybrids with thiazolidine‐2,4‐dione (KC21–KC36). These compounds were evaluated for FOXM1 inhibition. Molecular docking and molecular dynamics simulation analysis revealed their binding patterns and affinities for the FOXM1‐DNA binding domain. The interactions with key amino acids such as Asn283, His287, and Arg286, crucial for FOXM1 inhibition, have been determined with the synthesized compounds. Additionally, the molecular modeling study indicated that KC12, KC21, and KC30 aligned structurally and interacted similarly to the reference compound FDI‐6. In vitro studies with the MDA‐MB‐231 breast cancer cell line demonstrated that KC12, KC21, and KC30 significantly inhibited FOXM1, showing greater potency than FDI‐6, with IC50 values of 6.13, 10.77, and 12.86 µM, respectively, versus 20.79 µM for FDI‐6. Our findings suggest that KC12, KC21, and KC30 exhibit strong activity as FOXM1 inhibitors and may be suitable for in vivo animal studies.


  • Kaktüs Armut (Opuntia ficus-indica L.) Meyvesinden Stres Tolerant Mayaların Moleküler Tanımlanması ve Depo Karbonhidrat Birikimleri

    by Tulay Turgut Genc, Melih Günay, Merve Sikik 0000-0003-2552-038X

    Kaktüs armut bitkisi (Opuntia ficus-indica (L.) Mill.) yetiştiği coğrafya ve iklim koşulları nedeniyle sıcaklığa ve kuraklığa toleransı oldukça yüksek olan bir kaktüs türüdür. Bu kaktüs türünün bozulmaya başlayan kladotları ve meyveleri mayaların ve diğer mikroorganizmaların çoğalabilmesi için uygun alan oluşturmaktadır. Maya hücreleri stres koşullarında stres metaboliti olarak trehaloz ve glikojen biriktirir. Çalışmamızda kaktüs armut meyvesinden stres dirençli maya türlerinin izole edilerek moleküler yöntemlerle tanımlanması ve depo karbonhidrat birikimlerinin belirlenmesi amaçlandı. Termotolerant ve osmotolerant maya suşlarının moleküler tanımlanmasında 26S rDNA-D1/D2 gen bölgesinin dizi analizi kullanıldı. Stres dirençli maya suşlarının trehaloz ve glikojen birikimleri stres koşullarında enzimatik olarak belirlendi. İzole edilen K. marxianus, K. lactis ve P. kudriavzevii maya türlerine ait tüm maya suşlarının termotolerant ve osmotolerant maya suşları olduğu gözlendi. K. marxianus ve K. lactis maya türünde stres metaboliti olarak glikojenin P. kudriavzevii maya türünde ise trehalozun tercih edildiği belirlendi. Diğer izole edilen A. pullulans, H. opuntiae ve P. kluyveri türlerine ait maya suşları arasında stres toleransının ve depo karbonhidratın stresin derecesine ve çeşidine bağlı olarak değiştiği tespit edildi. İzole edilen K. marxianus ve K. lactis maya suşlarının süt ürünleri endüstrisinde, P. kudriavzevii maya suşlarının ise biyoetanol ve fermentasyon endüstrisinde kullanımı için uygun potansiyele sahip oldukları değerlendirildi.